58 Chapter 2 34. Kirtava A, Drews C, Lally C, Dilley A, Evatt B. Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand's disease receiving care in haemophilia treatment centres: a case-control study. Haemophilia. 2003;9(3):2927. doi:10.1046/j.1365-2516.2003.00756.x 35. Kouides PA, Phatak PD, Burkart P, et al. Gynaecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey. Haemophilia. 2000;6(6):643-8. doi:10.1046/j.1365-2516.2000.00447.x 36. Marshall AL, Dasari H, Warner ND, Grill DE, Nichols WL, Pruthi RK. Self-reported reproductive health experiences in women with von Willebrand disease: a qualitative interview-based study. J Obstet Gynaecol. 2019;39(2):288-290. doi:10. 1080/01443615.2018.1472223 37. Sumner M, Williams J. Type 3 von Willebrand disease: assessment of complications and approaches to treatment -- results of a patient and Hemophilia Treatment Center Survey in the United States. Haemophilia. 2004;10(4):360-6. doi:10.1111/ j.1365-2516.2004.00903.x 38. Barr RD, Sek J, Horsman J, et al. Health status and health-related quality of life associated with von Willebrand disease. Am J Hematol. 2003;73(2):108-14. doi:10.1002/ajh.10327 39. Rae C, Furlong W, Horsman J, et al. Bleeding disorders, menorrhagia and iron deficiency: impacts on health-related quality of life. Haemophilia. 2013;19(3):38591. doi:10.1111/hae.12014 40. Xu Y, Deforest M, Grabell J, Hopman W, James P. Relative contributions of bleeding scores and iron status on health-related quality of life in von Willebrand disease: a cross-sectional study. Haemophilia. 2017;23(1):115-121. doi:10.1111/hae.13062 41. Govorov I, Ekelund L, Chaireti R, et al. Heavy menstrual bleeding and healthassociated quality of life in women with von Willebrand's disease. Exp Ther Med. 2016;11(5):1923-1929. doi:10.3892/etm.2016.3144 42. Haghpanah S, Mohtadi H, Akbari M, Karimi M. Quality of Life in Children and Adolescents With Rare Bleeding Disorders in Southern Iran. Clin Appl Thromb Hemost. 2017;23(6):652-656. doi:10.1177/1076029616634887 43. Rydz N, James PD. The evolution and value of bleeding assessment tools. J Thromb Haemost. 2012;10(11):2223-9. doi:10.1111/j.1538-7836.2012.04923.x 44. James AH. More than menorrhagia: a review of the obstetric and gynaecological manifestations of bleeding disorders. Haemophilia. 2005;11(4):295-307. doi:10.1111/ j.1365-2516.2005.01108.x 45. Bruner AB, Joffe A, Duggan AK, Casella JF, Brandt J. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet. 1996;348(9033):992-6. doi:10.1016/S0140-6736(96)02341-0 46. de Wee EM, Sanders YV, Mauser-Bunschoten EP, et al. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thromb Haemost. 2012;108(4):683-92. doi:10.1160/TH12-04-0244 47. Federici AB. Clinical diagnosis of von Willebrand disease. Haemophilia. 2004;10 Suppl 4:169-76. doi:10.1111/j.1365-2516.2004.00991.x 48. van Galen KP, Mauser-Bunschoten EP, Leebeek FW. Hemophilic arthropathy in patients with von Willebrand disease. Blood Rev. 2012;26(6):261-6. doi:10.1016/j. blre.2012.09.002
RkJQdWJsaXNoZXIy MTk4NDMw